Résultats de la recherche - 5 results
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
confirmed by whole genome sequencing and vaccinated with a homologous (mRNA for prime/mRNA for boost) or heterologous (viral vector for prime/mRNA for boost) prime-boost vaccination schedule were included in ...
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
compared to viral vector vaccines: 66% and 80% for Ad26COV2.S and ChAdOx1 respectively (Alpha, 0-50 days after vaccination). Delta was associated with a 40% increase in odds of transmission and a decrease of ...
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
risk factors associated with breakthrough infections, such as vaccination with adenoviral-vector vaccines, which could help inform future decisions on booster vaccination strategies. A prior COVID-19 ...
Guideline for Pandemic COVID-19 Vaccine (Non-replicating Adenovirus-vectored vaccine)
Publication Type: Sci. report, recommendat°, guidance doc., directive, monograph Authors: L. Tesolin; EDQM OCABR drafting group Source: EDQM, EDQM, strasbourg, p.13 (2021) Accession Number: PA/PH/OMCL (21) 29 DEF Health Topics: Effectiveness and safety o ...
General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.
p.385-94 (2013) Keywords: Animals Clinical Trials as Topic Genetic Therapy Genetic Vectors Hazardous Substances Humans Organisms, Genetically Modified Risk Assessment Vaccination Viruses Abstract: This ...